Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.33)
# 1,011
Out of 4,918 analysts
103
Total ratings
51.67%
Success rate
2.99%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $90 → $100 | $105.19 | -4.93% | 1 | Jun 11, 2025 | |
| UTHR United Therapeutics | Initiates: Overweight | $405 | $286.99 | +41.12% | 1 | Jun 2, 2025 | |
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $4.23 | +207.33% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $56.98 | +57.96% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $458.55 | +4.68% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $44.06 | +24.84% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $112.07 | -28.62% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $3.64 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $559.15 | +81.53% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $294.39 | +37.57% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $391.20 | -43.76% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $9.83 | +1.73% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $3.73 | +74.26% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $54.53 | +32.04% | 1 | Apr 13, 2023 |
Verona Pharma
Jun 11, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $105.19
Upside: -4.93%
United Therapeutics
Jun 2, 2025
Initiates: Overweight
Price Target: $405
Current: $286.99
Upside: +41.12%
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $4.23
Upside: +207.33%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $56.98
Upside: +57.96%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $458.55
Upside: +4.68%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $44.06
Upside: +24.84%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $112.07
Upside: -28.62%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.64
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $559.15
Upside: +81.53%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $294.39
Upside: +37.57%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $391.20
Upside: -43.76%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $9.83
Upside: +1.73%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $3.73
Upside: +74.26%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $54.53
Upside: +32.04%